Sarcopenia impairs survival in patients with potentially curable hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 112, Issue 2, 2015, Pages 208-213

  Levolger, Stef ^a   Van Vledder, Mark G ^a   Muslem, Rahat ^a   Koek, Marcel ^a   Niessen, Wiro J ^a,b   De Man, Rob A ^a   De Bruin, Ron W F ^a   Ijzermans, Jan N M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

body composition; hepatocellular carcinoma; outcomes; radiofrequency ablation; sarcopenia; surgery

Indexed keywords

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; SARCOPENIA; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; NETHERLANDS; RADIOGRAPHY; SKELETAL MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NETHERLANDS; SARCOPENIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84940453801     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23976     Document Type: Article

References (30)

1. Prado CM, Lieffers JR, McCargar LJ, et al.,: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008; 9: 629-635.
2. Martin L, Birdsell L, Macdonald N, et al.,: Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31: 1539-1547.
3. Thoresen L, Frykholm G, Lydersen S, et al.,: Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr 2013; 32: 65-72.
4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al.,: Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing 2010; 39: 412-423.
5. Baumgartner RN, Koehler KM, Gallagher D, et al.,: Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-763.
6. Janssen I, Heymsfield SB, Ross R,: Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50: 889-896.
7. Cherin P, Voronska E, Fraoucene N, et al.,: Prevalence of sarcopenia among healthy ambulatory subjects: The sarcopenia begins from 45 years. Aging Clin Exp Res 2014; 26: 137-146.
8. van Vledder MG, Levolger S, Ayez N, et al.,: Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg 2012; 99: 550-557.
9. Sabel MS, Lee J, Cai S, et al.,: Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol 2011; 18: 3579-3585.
10. Peng PD, van Vledder MG, Tsai S, et al.,: Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 2011; 13: 439-446.
11. Dasarathy S,: Consilience in sarcopenia of cirrhosis. J Cachexia, Sarcopenia Muscle 2012; 3: 225-237.
12. Harimoto N, Shirabe K, Yamashita YI, et al.,: Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg 2013; 100: 1523-1530.
13. Itoh S, Shirabe K, Matsumoto Y, et al.,: Effect of body composition on outcomes after hepatic resection for hepatocellular carcinoma. Ann Surg Oncol 2014; 21: 3063-3068.
14. Iritani S, Imai K, Takai K, et al.,: Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol 2014.
15. Voron T, Tselikas L, Pietrasz D, et al.,: Sarcopenia impacts on short- and long-term results of Hepatectomy for hepatocellular carcinoma. Ann Surg 2014; 261: 1173-1183.
16. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al.,: Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 1985;1998 85: 115-122.
17. Dindo D, Demartines N, Clavien PA,: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213.
18. Montano-Loza AJ, Meza-Junco J, Baracos VE, et al.,: Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl 2014; 20: 640-648.
19. Englesbe MJ, Patel SP, He K, et al.,: Sarcopenia and mortality after liver transplantation. J Am Coll Surg 2010; 211: 271-278.
20. Krell RW, Kaul DR, Martin AR, et al.,: Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl 2013; 19: 1396-1402.
21. Zamboni M, Mazzali G, Fantin F, et al.,: Sarcopenic obesity: A new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 2008; 18: 388-395.
22. Korchynskyi O, Landstrom M, Stoika R, et al.,: Expression of Smad proteins in human colorectal cancer. Int J Cancer 1999; 82: 197-202.
23. Marcus RL, Brixner DI, Ghate S, et al.,: Fat modulates the relationship between sarcopenia and physical function in nonobese older adults. Curr Gerontol Geriatr Res 2012; 2012: 216185.
24. Malmstrom TK, Miller DK, Herning MM, et al.,: Low appendicular skeletal muscle mass (ASM) with limited mobility and poor health outcomes in middle-aged African Americans. J Cachexia Sarcopenia Muscle 2013; 4: 179-186.
25. Carey EJ, Steidley DE, Aqel BA, et al.,: Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 2010; 16: 1373-1378.
26. Fearon KC, Glass DJ, Guttridge DC,: Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab 2012; 16: 153-166.
27. Argiles JM, Busquets S, Stemmler B, et al.,: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer 2014; 14: 754-762.
28. Zhou X, Wang JL, Lu J, et al.,: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010; 142: 531-543.
29. Jameson GS, Hoff DDV, Weiss GJ, et al.,: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J Clin Oncol 2012; 30.
30. Dingemans AM, de Vos-Geelen J, Langen R, et al.,: Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs 2014; 23: 1655-1669.